Fixed Panels

Oncoscreen /Oncocompass IO

Our most comprehensive assay panel, screening for 520 clinically relevant genes as determined and recommended by the National Comprehensive Cancer Network. This gene panel screens for the majority of all actionable genetic mutations of interest within the oncology therapeutic development space.

Compatible with both tissue (Oncoscreen IO) and blood-based (Oncocompass IO) samples, the breadth of this diagnostic test allows for evaluation of complex biomarkers such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD) as well as detection of specific rare mutations such as NTRK1-3 rearrangements, ALK fusions, and KRAS point mutations for treatment guidance of both targeted therapies and immunotherapies.

TMB (FDA approved June 2020) as a biomarker measures the total number of mutations found in DNA in cancer cells, and thus, gives predictive and prognostic value for determining cancer therapy. As this is our most comprehensive panel, Oncoscreen IO has applications for almost all cancer types. It can provide accurate genomic profiling for both clinical trial patient selection as well as therapy response monitoring.

Cancer Types and Genetic Biomarkers

Oncoscreen/Oncocompass Target

A more focused panel, Oncoscreen Target screens for an array of 168 clinically actionable predictive biomarkers. It has the capability to assess the complex biomarker MSI, as well as genetic mutations including those of EGFR, ATM, and MET, as well as genetic rearrangements including those of NTRK1-3, ROS1, and RET. It is available for diagnosis of both tissue (Oncoscreen Target) and blood-based (Oncocompass Target) samples. This panel has applications for a large variety of cancer types including melanoma, lung, breast, prostate, and liver cancer. It can provide comprehensive genomic profiling for clinical trial patient selection as well as therapy response monitoring, and is currently being used for biomarker detection for Tagrisso® (osimertinib) and Afatinib.

Cancer Types

Oncoscreen Focus

Our OncoScreen Focus panel is used primarily in Lung Cancer applications as a test to screen prospective patients for clinical trials, help guide therapy selection, and also for studies around the world for lung cancer researchers. It screens for 13 of the most actionable genes highly involved in lung cancers including EGFR, MET, and ROS1. It is available for diagnosis for tissue-based samples.

Cancer Types